Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 7, July, p. 921–927

doi: 10.17219/acem/68985

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

PIK3R1 gene polymorphisms are associated with type 2 diabetes and related features in the Turkish population

Abdullah Hakan Karadoğan1,A,B,C, Hilal Arikoglu1,A,C,D,E,F, Fatma Göktürk1,B, Funda İşçioğlu2,C, Süleyman Hilmi İpekçi3,B

1 Department of Medical Biology, Faculty of Medicine, Selçuk University, Konya, Turkey

2 Department of Statistics, Faculty of Science, Ege University, Izmir, Turkey

3 Department of Endocrinology, Faculty of Medicine, Selçuk University, Konya, Turkey

Abstract

Background. The phosphatidylinositol 3-kinase p85 alpha regulatory subunit 1 gene (PIK3R1) encodes the PIK3R1 protein, which plays a direct role in insulin signaling. PIK3R1 (p85 regulatory subunit) connects firmly with the p110 catalytic subunit, and together these proteins form the phosphatidylinositol 3-kinase (PI3K) protein. PI3K is a key protein in the Akt signaling pathway, which regulates cell survival, growth, differentiation, glucose trafficking, and utilization. Defects in the insulin signaling cascade play an important role in the development of insulin resistance, which shares a common genetic basis for metabolic diseases such as type 2 diabetes (T2D), obesity and cardiovascular diseases.
Objectives. In our study, we investigated the effect of single nucleotide polymorphisms (SNPs) rs3756668 in 3’UTR region, rs706713 and rs3730089 in exons 1 and 6, respectively, rs7713645 and rs7709243 in intron 1, and rs1550805 in intron 6 of PIK3R1 gene on T2D.
Material and Methods. This study enrolled a total of 840 individuals, including 427 diabetic individuals (206 obese and 221 non-obese) and 413 nondiabetic individuals (138 obese and 275 non-obese). The target SNPs were analyzed using real-time polymerase chain reaction (RT-PCR). Statistical analysis was performed using SPSS18.0 (IBM Corp., Armonk, USA). The p-values ≤0.05 were considered statistically significant.
Results. The SNPs rs706713 (Tyr73Tyr) and rs3730089 (Met326Ile) located in exons, and rs7713645, rs7709243 and rs1550805 located in introns were determined to be significantly associated with T2D and phenotypic features such as obesity, insulin resistance and the lipid parameters. The association with SNP rs3756668, which is located in the 3’UTR, was not significant.
Conclusion. Our study supports the role of PIK3R1, an important candidate gene due to its critical role in insulin signal transduction, in T2D development.

Key words

type 2 diabetes, single nucleotide polymorphisms, PIK3R1 gene

References (30)

  1. Klippel A, Reinhard C, Kavanaugh WM, Apell G, Escobedo MA, Williams LT. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol Cell Biol. 1996;16(8):4117–4127.
  2. Rojek A, Niedziela M. Insulin receptor and its relationship with different forms of insulin resistance. Adv Cell Biol. 2010;2:59–90.
  3. Honardoost M, Sarookhani MR, Arefian E, Soleimani M. Insulin resistance associated genes and miRNA. Appl Biochem Biotechnol. 2014;174(1):63–80.
  4. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome – an allostatic perspective. Biochim Biophys Acta. 2010;1801(3):338–349.
  5. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM. Regulation of the p85/p110 phosphatidylinositol 3-kinase: Stabilization and inhibition of the p110a catalytic subunit by the p85 regulatory subunit. Mol Cell Biol. 1998;18(3):1379–1387.
  6. Małodobra M, Pilecka A, Gworys B, Adamiec R. Single nucleotide polymorphisms within functional regions of genes implicated in insulin action and association with the insulin resistant phenotype. Mol Cell Biochem. 2011;349(1–2):187–193.
  7. Chen JM, Férec C, Cooper DN. A systematic analysis of disease-associated variants in the 30 regulatory regions of human protein-coding genes II: The importance of mRNA secondary structure in assessing the functionality of 30 UTR variants. Hum Genet. 2006;120(3):301–333.
  8. Nelsoe RL, Hamid YH, Pociot F, et al. Association of a microsatellite in FASL to type 2 diabetes and of the FAS-670G>A genotype in insulin resistance. Genes Immun. 2006;7:316–321.
  9. Gaunt TR, Rodriguez S, Zapata C, Day IN. MIDAS: Software for analysis and visualisation of interallelic disequilibrium between multiallelic markers. BMC Bioinformatics. 2006;27:227. doi: 10.1186/1471-2105-7-227
  10. Kahn CR. The molecular mechanism of insulin action. Annu Rev Med. 1985;36:429–451.
  11. Dhe-Paganon S, Ottinger EA, Nolte RT, Eck MJ, Shoelson SE. Crystal structure of the pleckstrin homology-phosphotyrosine binding (PH-PTB) targeting region of insulin receptor substrate 1. Proc Natl Acad Sci. 1999;96(15):8378–8383.
  12. Isakoff SJ, Taha C, Rose E, Marcusohn J, Klip A, Skolnik EY. The inability of phosphatidylinositol 3-kinase activation to stimulate GLUT4 translocation indicates additional signaling pathways are required for insulin-stimulated glucose uptake. Proc Natl Acad Sci USA. 1995;92(22):10247–10251.
  13. Perry RJ, Shulman GI. Treating fatty liver and insulin resistance. Aging. 2013;5(11):791–792.
  14. Knights AJ, Funnell AP, Pearson RC, Crossley M, Bell-Anderson KS. Adipokines and insulin action: A sensitive issue. Adipocyte. 2014;3(2):88–96.
  15. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271(5249):665–668.
  16. Bogan JS, Lodish HF. Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. J Cell Biol. 1999;146(3):609–620.
  17. Chagnon YC, Rankinen T, Snyder EE, Weisnagel SJ, Pe’russe L, Bouchard C. The human obesity gene map: The 2002 update. Obes Res. 2003;11(3):313–367.
  18. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174(9):5789–5795.
  19. Ueki K, Yballe CM, Brachmann SM, et al. Increased insulin sensitivity in mice lacking p85 beta subunit of phosphoinositide 3-kinase. PNAS. 2002;99(1):419–424.
  20. Barbour LA, Shao J, Qiao L, et al. Human placental growth hormone increases expression of the P85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Endocrinology. 2004;145(3):1144–1150.
  21. Giorgino F, Pedrini MT, Matera L, Smith RJ. Specific increase in p85a expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-1 stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J Biol Chem. 1997;272(11):7455–7463.
  22. Rai E, Sharma S, Kaul S, et al. The interactive effect of SIRT1 promoter region polymorphism on type 2 diabetes susceptibility in the north Indian population. Plos One. 2012;7(11):e48621. doi: 10.1371/journal.pone.0048621
  23. Jamshidi Y, Snieder H, Wang X, et al. Phosphatidylinositol 3-kinase p85 alpha regulatory subunit gene PIK3R1 haplotype is associated with body fat and serum leptin in a female twin population. Diabetologia. 2006;49(11):2659–2667.
  24. Hansen L, Zethelius B, Berglund L, et al. In vitro and in vivo studies of a naturally occurring variant of the human p85a regulatory subunit of the phosphoinositide 3-kinase. Inhibition of protein kinase b and relationships with type 2 diabetes, insulin secretion, glucose disappearance constant, and insulin sensitivity. Diabetes. 2001;50:691–693.
  25. Chen S, Yan W, Huang J, Ge D, Yao Z. Association analysis of the variant in the regulatory subunit of phosphoinositide 3-kinase (p85a) with type 2 diabetes mellitus and hypertension in the Chinese Han population. Diabet Med. 2005;22(6):737–743.
  26. Hancock AM, Witonsky DB, Gordon AS, et al. Adaptations to climate in candidate genes for common metabolic disorders. PLoS Genet. 2008;4(2):e32. doi: 10.1371/journal.pgen.0040032
  27. Fruman DA, Cantley LC. Phosphoinositide 3-kinase in immunological systems. Semin Immunol. 2002;14(1):7–18.
  28. Pang DX, Smith AJP, Humphries SE. Functional analysis of TCF7L2 genetic variants associated with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2013;23(6):550–556.
  29. Hossain S, Islam S, Khatun T, Sapon A. Type 2 diabetes mellitus: Impact of genetics and environment. Int J Curr Sci. 2014;12:110–127.
  30. Małodobra M. The role of single nucleotide polymorphisms of untranslated regions (Utrs) in insulin resistance pathogenesis in patients with type 2 diabetes. In: Croniger C, ed. Medical Complications of Type 2 Diabetes. London, UK: InTech; 2011:165–188.
© Wroclaw Medical University